Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Cureskin aims to disrupt the large and growing skin and hair care industry in India
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
It is the first autotaxin inhibitor to be investigated in cancer patients
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
The facility will accommodate over 1,500 employees
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
Subscribe To Our Newsletter & Stay Updated
